G1 Therapeutics Inc
GTHX
Get informed when a big investor buys or sells
+ FollowMarket Cap$377.75M
Close$
$10.62
48.3% upside
Current Fair Value
48.3% upsideUndervalued by 48.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $377.75 Million |
|---|---|
| Enterprise Value | $378.68 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.93 |
| Beta | 1.68 |
| Outstanding Shares | 52,475,190 |
Return
| Return on Equity | -182.05% |
|---|---|
| Return on Assets | -45.36% |
| Return on Invested Capital | -62.12% |
Valuation & Multiples
| P/E Ratio | -7.72 |
|---|---|
| PEG | 4.74 |
| Price to Sales | 7.16 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.51 |
| Enterprise Value to EBIT | -9.96 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.65 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About G1 Therapeutics Inc
CEO: Mark Velleca